End-of-day quote
Taipei Exchange
18:00:00 2024-05-16 EDT
|
5-day change
|
1st Jan Change
|
83.1
TWD
|
+2.34%
|
|
+3.88%
|
-17.31%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
4,647
|
9,700
|
33,476
|
37,428
|
30,748
|
25,442
|
-
|
Enterprise Value (EV)
1 |
5,338
|
9,800
|
26,978
|
31,421
|
30,748
|
20,109
|
20,185
|
P/E ratio
|
-5.09
x
|
-8.69
x
|
-619
x
|
-324
x
|
-33.5
x
|
76.2
x
|
61.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
9.76
x
|
9.05
x
|
19.7
x
|
25.3
x
|
30.1
x
|
11.1
x
|
9.33
x
|
EV / Revenue
|
11.2
x
|
9.14
x
|
15.9
x
|
21.2
x
|
30.1
x
|
8.8
x
|
7.4
x
|
EV / EBITDA
|
-7.27
x
|
-12
x
|
220
x
|
-243
x
|
-38.8
x
|
32
x
|
-
|
EV / FCF
|
-4.48
x
|
-21.4
x
|
-137
x
|
-63.7
x
|
-
|
-68.5
x
|
1,682
x
|
FCF Yield
|
-22.3%
|
-4.67%
|
-0.73%
|
-1.57%
|
-
|
-1.46%
|
0.06%
|
Price to Book
|
2.51
x
|
5.09
x
|
3.21
x
|
3.5
x
|
-
|
2.46
x
|
2.39
x
|
Nbr of stocks (in thousands)
|
169,284
|
206,375
|
300,232
|
304,290
|
305,946
|
306,161
|
-
|
Reference price
2 |
27.45
|
47.00
|
111.5
|
123.0
|
100.5
|
83.10
|
83.10
|
Announcement Date
|
3/29/20
|
3/25/21
|
3/30/22
|
3/20/23
|
3/22/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
476.1
|
1,072
|
1,697
|
1,481
|
1,023
|
2,286
|
2,726
|
EBITDA
1 |
-734
|
-813.9
|
122.4
|
-129.2
|
-793.1
|
628
|
-
|
EBIT
1 |
-847.7
|
-986
|
-60.52
|
-333.4
|
-1,032
|
434
|
282
|
Operating Margin
|
-178.05%
|
-91.99%
|
-3.57%
|
-22.51%
|
-100.91%
|
18.99%
|
10.34%
|
Earnings before Tax (EBT)
1 |
-860.9
|
-1,041
|
-42.39
|
-115.2
|
-913.6
|
467
|
413
|
Net income
1 |
-860.9
|
-1,042
|
-42.58
|
-115.5
|
-915.2
|
332
|
413
|
Net margin
|
-180.83%
|
-97.19%
|
-2.51%
|
-7.8%
|
-89.49%
|
14.52%
|
15.15%
|
EPS
2 |
-5.390
|
-5.410
|
-0.1800
|
-0.3800
|
-3.000
|
1.090
|
1.350
|
Free Cash Flow
1 |
-1,192
|
-457.4
|
-196.6
|
-493.3
|
-
|
-293.5
|
12
|
FCF margin
|
-250.4%
|
-42.68%
|
-11.58%
|
-33.31%
|
-
|
-12.84%
|
0.44%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
2.91%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/29/20
|
3/25/21
|
3/30/22
|
3/20/23
|
3/22/24
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
656.6
|
423.5
|
361.5
|
336.6
|
361.6
|
421.3
|
216.3
|
138.3
|
211.5
|
456.6
|
219.7
|
380
|
712.5
|
735.5
|
EBITDA
1 |
366
|
54.15
|
12.95
|
-35.58
|
-89.36
|
-17.24
|
-162.9
|
-198.3
|
-141.4
|
-
|
-141
|
118
|
156
|
512
|
EBIT
1 |
320.2
|
7.657
|
-35.19
|
-85.45
|
-141.8
|
-71.01
|
-220.5
|
-255.9
|
-199.4
|
-356.2
|
-214
|
-88
|
215
|
196.5
|
Operating Margin
|
48.76%
|
1.81%
|
-9.73%
|
-25.39%
|
-39.2%
|
-16.85%
|
-101.91%
|
-185.03%
|
-94.29%
|
-78.02%
|
-97.42%
|
-23.16%
|
30.18%
|
26.72%
|
Earnings before Tax (EBT)
1 |
332.3
|
2.182
|
14.19
|
6.787
|
-27.16
|
-109
|
-203.2
|
-193.6
|
-111.3
|
-405.5
|
-103.6
|
-66.5
|
237
|
214
|
Net income
1 |
332.1
|
3.094
|
13.85
|
6.418
|
-27.56
|
-108.2
|
-203.5
|
-194.1
|
-111.7
|
-405.9
|
-104
|
-75
|
224.5
|
167
|
Net margin
|
50.57%
|
0.73%
|
3.83%
|
1.91%
|
-7.62%
|
-25.69%
|
-94.07%
|
-140.3%
|
-52.84%
|
-88.91%
|
-47.35%
|
-19.74%
|
31.51%
|
22.71%
|
EPS
2 |
1.340
|
0.0200
|
0.0500
|
0.0200
|
-0.0900
|
-0.3600
|
-0.6700
|
-0.6400
|
-0.3700
|
-1.330
|
-0.3400
|
-0.2450
|
0.7400
|
0.5500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/12/21
|
3/30/22
|
5/13/22
|
8/12/22
|
11/11/22
|
3/20/23
|
5/15/23
|
8/9/23
|
11/13/23
|
3/22/24
|
5/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
691
|
100
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
6,498
|
6,006
|
-
|
5,333
|
5,257
|
Leverage (Debt/EBITDA)
|
-0.941
x
|
-0.1233
x
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-1,192
|
-457
|
-197
|
-493
|
-
|
-294
|
12
|
ROE (net income / shareholders' equity)
|
-43.7%
|
-55.4%
|
-0.69%
|
-1.09%
|
-
|
3.3%
|
3.9%
|
ROA (Net income/ Total Assets)
|
-26.9%
|
-28.7%
|
-0.56%
|
-0.99%
|
-
|
2.9%
|
3.6%
|
Assets
1 |
3,197
|
3,626
|
7,638
|
11,644
|
-
|
11,448
|
11,472
|
Book Value Per Share
2 |
11.00
|
9.230
|
34.70
|
35.10
|
-
|
33.80
|
34.80
|
Cash Flow per Share
2 |
-4.630
|
-2.180
|
-0.1300
|
-0.4900
|
-
|
1.320
|
-
|
Capex
1 |
408
|
38.1
|
167
|
346
|
-
|
457
|
612
|
Capex / Sales
|
85.71%
|
3.56%
|
9.82%
|
23.35%
|
-
|
19.97%
|
22.45%
|
Announcement Date
|
3/29/20
|
3/25/21
|
3/30/22
|
3/20/23
|
3/22/24
|
-
|
-
|
Last Close Price
83.1
TWD Average target price
132.5
TWD Spread / Average Target +59.45% Consensus |
1st Jan change
|
Capi.
|
---|
| -17.31% | 773M | | -2.32% | 92.59B | | +3.16% | 41.43B | | -11.90% | 33.49B | | -20.43% | 14.62B | | -9.56% | 12.77B | | -11.34% | 11.58B | | -44.00% | 11.35B | | +3.97% | 8.97B | | -6.32% | 8.3B |
Biopharmaceuticals
|